Abiopharma

🔍 Du Ying (Executive)

Company: Zai Lab Ltd (ZLAB)

Report Date: 2026-03-06

Detailed Transactions and Holdings:

• Acquired 50,000 shares of American Depositary Shares at $1.74 per share (Direct)
  Date: 2026-03-06 | Code: M | equity_swap_involved: false | shares_owned_after: 1,014,161.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 50,000 shares of American Depositary Shares at $19.4187 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: false | shares_owned_after: 964,161.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Acquired 50,000 shares of American Depositary Shares at $1.74 per share (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: false | shares_owned_after: 1,014,161.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 50,000 shares of American Depositary Shares at $19.0293 per share (Direct)
  Date: 2026-03-09 | Code: S | equity_swap_involved: false | shares_owned_after: 964,161.00 | transaction_form_type: 4 | Footnotes: F1, F2, F4
• Sold 50,000 shares of Stock Options (Right to Buy) at $1.74 per share (Derivative)
  Date: 2026-03-06 | Code: M | Expires: 2026-08-25 | equity_swap_involved: false | shares_owned_after: 772,184.00 | transaction_form_type: 4 | Footnotes: F5, F1
• Sold 50,000 shares of Stock Options (Right to Buy) at $1.74 per share (Derivative)
  Date: 2026-03-09 | Code: M | Expires: 2026-08-25 | equity_swap_involved: false | shares_owned_after: 722,184.00 | transaction_form_type: 4 | Footnotes: F5, F1

Footnotes:

• F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
• F2: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2025.
• F3: Reflects a weighted average sale price of $19.4187 per share, at prices ranging from $19.04 to $19.68 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F4: Reflects a weighted average sale price of $19.0293 per share, at prices ranging from $18.78 to $19.25 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F5: The option vested in equal annual installments over five years beginning on August 25, 2017, the first anniversary of the date of grant.